For research use only. Not for therapeutic Use.
Enavogliflozin (Cat No.:I026841) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor developed for the treatment of type 2 diabetes mellitus. By blocking SGLT2 in the kidneys, it inhibits the reabsorption of glucose, leading to increased urinary glucose excretion and subsequent reduction in blood glucose levels. Enavogliflozin aids in improving glycemic control and is often used in conjunction with diet and exercise. As a member of the SGLT2 inhibitor class, it is recognized for its potential to lower blood glucose levels and promote weight loss in patients with type 2 diabetes.
| Catalog Number | I026841 |
| CAS Number | 1415472-28-4 |
| Synonyms | Enavogliflozin |
| Molecular Formula | C24H27ClO6 |
| Purity | 98% |
| Target | SGLT |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| IUPAC Name | (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| InChI | InChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1 |
| InChIKey | KORCWPOBTZTAFI-YVTYUBGGSA-N |
| SMILES | ClC1=C2C(CCO2)=C([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1CC4=CC=C(C5CC5)C=C4 |
| Reference | 1: Markiewicz M, Jungnickel C, Stolte S, Białk-Bielińska A, Kumirska J, Mrozik W. Ultimate biodegradability and ecotoxicity of orally administered antidiabetic drugs. J Hazard Mater. 2017 Jul 5;333:154-161. doi: 10.1016/j.jhazmat.2017.03.030. Epub 2017 Mar 16. PubMed PMID: 28349868. |
